Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ombitasvir + paritaprevir + ritonavir
- Development stage
- Phase 3
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Ombitasvir + paritaprevir + ritonavir** is an oral fixed-dose direct-acting antiviral combination for chronic hepatitis C virus infection. Ombitasvir inhibits hepatitis C virus NS5A, paritaprevir inhibits the viral NS3/4A protease, and ritonavir inhibits CYP3A to increase paritaprevir exposure. It was marketed by AbbVie as Technivie in the United States and Viekirax in Europe, generally with ribavirin for genotype 4 infection and, in some settings, with dasabuvir for genotype 1 infection. Technivie and Viekirax have since been discontinued or withdrawn from their principal markets for commercial reasons. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207931s013lbl.pdf))
- Brand names
- Viekirax
- Other names
- 2D regimenOBV/PTV/rOPrombitasvir + paritaprevir + ritonavirombitasvir/paritaprevir/ritonavirparitaprevir/ritonavir/ombitasvir
02
Targets
CYP3A4 (Cytochrome P450 3A4)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on ombitasvir + paritaprevir + ritonavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ombitasvir + paritaprevir + ritonavir.